Investigators for both studies said ongoing analyses will help put the divergent management strategies into better context.

Despite the positive results, there are open questions about LBB pacing, including long-term lead performance. RCTs are ...

Our coverage of ACC 2025 in Chicago dominated our most-read stories, but other news on novel therapies made the list, too.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha ...